SGN-CD33A (Vadastuximab Talirine) followed by Allogeneic Hematopoietic Stem Cell Transplant (AlloHSCT) Results in Durable Complete Remissions (CRs) in Patients with Acute Myeloid Leukemia (AML)
Publication
, Conference
Stein, AS; Walter, RB; Advani, AS; Ho, PA; Erba, HP
Published in: Biology of Blood and Marrow Transplantation
March 2016
Duke Scholars
Published In
Biology of Blood and Marrow Transplantation
DOI
ISSN
1083-8791
Publication Date
March 2016
Volume
22
Issue
3
Start / End Page
S211 / S212
Publisher
Elsevier BV
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Stein, A. S., Walter, R. B., Advani, A. S., Ho, P. A., & Erba, H. P. (2016). SGN-CD33A (Vadastuximab Talirine) followed by Allogeneic Hematopoietic Stem Cell Transplant (AlloHSCT) Results in Durable Complete Remissions (CRs) in Patients with Acute Myeloid Leukemia (AML). In Biology of Blood and Marrow Transplantation (Vol. 22, pp. S211–S212). Elsevier BV. https://doi.org/10.1016/j.bbmt.2015.11.608
Stein, Anthony S., Roland B. Walter, Anjali S. Advani, Phoenix A. Ho, and Harry P. Erba. “SGN-CD33A (Vadastuximab Talirine) followed by Allogeneic Hematopoietic Stem Cell Transplant (AlloHSCT) Results in Durable Complete Remissions (CRs) in Patients with Acute Myeloid Leukemia (AML).” In Biology of Blood and Marrow Transplantation, 22:S211–12. Elsevier BV, 2016. https://doi.org/10.1016/j.bbmt.2015.11.608.
Stein AS, Walter RB, Advani AS, Ho PA, Erba HP. SGN-CD33A (Vadastuximab Talirine) followed by Allogeneic Hematopoietic Stem Cell Transplant (AlloHSCT) Results in Durable Complete Remissions (CRs) in Patients with Acute Myeloid Leukemia (AML). In: Biology of Blood and Marrow Transplantation. Elsevier BV; 2016. p. S211–2.
Stein, Anthony S., et al. “SGN-CD33A (Vadastuximab Talirine) followed by Allogeneic Hematopoietic Stem Cell Transplant (AlloHSCT) Results in Durable Complete Remissions (CRs) in Patients with Acute Myeloid Leukemia (AML).” Biology of Blood and Marrow Transplantation, vol. 22, no. 3, Elsevier BV, 2016, pp. S211–12. Crossref, doi:10.1016/j.bbmt.2015.11.608.
Stein AS, Walter RB, Advani AS, Ho PA, Erba HP. SGN-CD33A (Vadastuximab Talirine) followed by Allogeneic Hematopoietic Stem Cell Transplant (AlloHSCT) Results in Durable Complete Remissions (CRs) in Patients with Acute Myeloid Leukemia (AML). Biology of Blood and Marrow Transplantation. Elsevier BV; 2016. p. S211–S212.
Published In
Biology of Blood and Marrow Transplantation
DOI
ISSN
1083-8791
Publication Date
March 2016
Volume
22
Issue
3
Start / End Page
S211 / S212
Publisher
Elsevier BV
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences